SS-31 (Elamipretide / MTP-131) is a mitochondria-targeting tetrapeptide that selectively concentrates in the inner mitochondrial membrane where it binds cardiolipin u2014 a phospholipid essential for cristae structure and electron transport chain (ETC) efficiency. It reduces electron leak and ROS production while increasing ATP synthesis efficiency.
Overview
Reconstitution Table (1 mL mL BAC water u2192 500 mcg)
| Weight | Dose | Draw (U-100) |
| 70 kg | 17.5 mg | ~35 Units |
| 80 kg | 20 mg | ~40 Units |
Reconstitute 500 mcg with 1 mL saline u2192 500 mcg/mL. Most research dosing is weight-based. Inject SC.
SS-31 (Elamipretide) is in Phase II/III clinical trials for heart failure and Barth syndrome. Research use only outside approved trials.
Potential Benefits & Side Effects
Potential Benefits
- Mitochondrial cristae structure preservation
- ROS reduction
- ATP synthesis improvement
- Cardiac function support
- Exercise capacity improvement (clinical data)
Possible Side Effects
- Injection-site reactions
- Limited long-term data in humans
Storage Instructions
Lyophilized Powder
- Short-term (<3 months): Refrigerate at 2u00b0Cu20138u00b0C
- Long-term: Freeze at u221220u00b0C or lower
- Protect from light and moisture
- Allow vial to reach room temperature before opening
Reconstituted Solution
- Refrigerate at 2u00b0Cu20138u00b0C u2014 do not freeze
- Use within 28 days when reconstituted with BAC water
- Always use sterile technique when drawing doses
References
Important Note
This protocol guide is for educational and research purposes only. It is not medical advice. Always consult a qualified healthcare professional before using any peptide compound.